 BEC 5 Curaderm - the clinically proven, cost effective treatment for both primary and secondary skin cancer care.
BEC 5 contains a specially purified plant extract from the maeum, (the so-called Devil’s apple) which is found in the Australasia region. The extract itself, known as Solasodine Glycosides, (at a strength of 0.005%) is also found in the eggplant and aubergine (albeit in smaller quantities).
After two decades of research and clinical trials, biochemist, Dr. Bill E. Cham, has discovered that BEC5 when applied topically can eradicate non-melanoma skin cancers, specifically:
1. Basal cell carcinomas (BCC).
2. Squamous cell carcinomas (SCC).
BEC5 cream has also been shown to be efficacious with benign tumours and other skin irregularities, including:
1. Keratoses.
2. Keratoacanthomas.
3. Sun spots.
4. Age spots.
Numerous clinical trials in Australia and Great Britain have confirmed BEC5’s ability to regress non-melanoma skin cancers. In one open study with 72 patients, treatment with BEC5 Curaderm cream resulted in the regression of all treated lesions (56 actinic keratoses, 39 BCCs and 29 SCCs), with 100% healed after 1 to 13 weeks of treatment.
Recent trials in 10 UK hospitals found that a twice daily topical application of BEC5 Curaderm cream to the affected areas gave a complete remission to 78% of the patients within 8-weeks. The remaining 22% of patients had also improved and needed longer treatment times. All this was made possible without chemotherapy, radiotherapy or surgery.
The dermatologists at the Royal London Hospital concluded that: “BEC5 is a topical preparation which is safe and effective, an ideal therapy for outpatient treatment... It is a cost effective treatment for both primary and secondary skin cancer care.”
Furthermore, the histological analyses of biopsies taken before, during and after treatment give compelling evidence of the continuing efficacy of BEC5 because treated skin cancer lesions have not recurred for at least 5-years after cessation of therapy.
BEC5 Curaderm cream is therefore recommended to be used to treat areas of the skin that may have become discoloured, thickened or scaly as a result of exposure to sun (UV) light. These areas of the skin are known as keratoses. BEC5 Curaderm cream is effective to treat true malignant skin cancers such as the non-melanoma basal cell carcinoma and squamous cell carcinoma. To date, it is estimated that more than 80,000 people have used BEC5 and shown below are just some of the results achieved with BEC5 cream:
BEC5 works because it contains a plant sugar called rhamnose, (which is not usually found in mammalian species). Specific endogenous lectins, (which are receptors for the sugar part of the glycoalkaloids) are present in the plasma membranes of susceptible cancer cells, but they not present in normal cells. Therefore BEC5 recognizes and binds the sugar rhamnose of the glycoalkaloid to the cancer cell. Subsequently, this enters the cancer cell and causes cell death by destroying the lysosome.
Apart from the remarkable results in the treatment of skin cancers, BEC5’s efficacy to help remove and protect against sun spots represents a major step forward in the prevention and “control” of skin cancers. Its ease of use, cost effectiveness, proven efficacy and safety all represent a very significant breakthrough for the majority of skin carcinomas, which are by far the most common forms of cancer.
Dosage: A 20 ml. bottle of BEC5 Curaderm should be enough to treat one large skin cancer, two medium sized ones, six small ones or twelve sun spots.
Safety: Side effects to date have been limited to skin reddening, although during treatment erosion, ulceration and shedding of unwanted skin cells is also likely to take place.
Clean the area to be treated with a mild antiseptic (to remove old skin cells). BEC5 should be applied relatively thickly to the area at least twice daily and a micro pore placed over the area. The eyes should be avoided. If any excess occurs, wash and wipe away with cold water. Application should continue for a minimum of 7 days and a maximum of 60 days, the duration is dependant upon the size, need and regularity of application.
BEC5 Curaderm should not be applied to moles and melanomas. Furthermore, BEC5 should not be used by persons who are allergic to eggplant or aspirin.
Persons taking prescription medication and pregnant or lactating women should consult a physician before using this product. Long-term use of this product should be supervised and monitored by a health care professional.
Disclaimer: This product and its statements have not been evaluated by the FDA. This product is not intended to treat, cure or prevent any disease. The above information is provided under the supplying company's terms and conditions and should not replace the advice of your personal physician.
Restrictions: This product is not available for shipment to the UK
CLICK HERE TO BUY
Clinical trials - more...
The dermatologists who conducted the Phase III clinical trials with BEC5 Curaderm concluded that BEC5 is a topical preparation, which is safe and effective.
BEC 5 therapy is ideal for outpatient treatment and is a much needed alternative to surgery for BCC. The clinical trials of BEC5 done by the multi-centres, comprised of application of BEC5 twice daily for eight weeks. Phase III clinical trials involving ten centres in the United Kingdom were completed in 2002. The general success rate of the glycoalkaloid (BEC) cream was 78 percent. Longer duration therapy with BEC would have resulted in higher success rates. These results were comparable to Clincal Trials 1 & 2 and independent doctor studies into Curaderm previously obtained over the last 20 years.
Clinical Trial Centres and Study Investigators
Dr R Cerio, The Royal London Hospital
Professor A Finlay, University of Wales College of Medicine
Dr R A C Graham-Brown, Leicester Royal Infirmary
Dr J Hawk, St Thomas Hospital
Dr M Rustin, Royal Free Hospital
Dr D L Roberts, Singleton Hospital
Dr P Kersey, Derriford Hospital
Professor C E M Griffiths, Hope Hospital
Dr L J Cook, St Mary's Hospital, Portsmouth
Dr G R Sharpe, Royal Liverpool Hospital, Liverpool
By Using Curaderm YOU DO NOT NEED Surgery, Radiotherapy or other Conventional Methods. Plastic surgeons, radiotherapists and dermatologists jointly manage BCCs, which are slow growing, locally invasive malignant skin tumors.
To date such management usually involves surgery. It must also be stressed that the risks of surgical intervention are well known. Moreover, excision of BCC from the facial area often involves reconstructive surgery, which can be both time consuming and costly. The dermatologists who conducted the Phase III clinical trials with BEC 5 concluded that BEC5 is a topical preparation, which is safe and effective. BEC 5 therapy is ideal for outpatient treatment and is a much needed alternative to surgery for BCC.
Tens of thousands NO longer need to lose skin and body Parts.
Curaderm has Clinical Proven Effectiveness.
Following two decades Dr. Cham's group first reported the efficacy and safety of BEC01 and Curaderm for the treatment of non malignant and invasive malignant skin cancer, the skin specialists who conducted the clinical trials have realized the true benefits of Curaderm.
Tens of thousands of patients have unnecessarily lost their noses, eyes, ears, and some even their lives, because Curaderm cream was not recommended for use! The definite outcome to having an effective treatment for skin cancer using a cream is now about allowing the general public to benefit from Curaderm's real value for patients.
The clinical trial experience has shown that the BEC was safe. Only local skin irritation and erythema (reddening) occurred during treatment. Success was defined as zero presence of basal cell carcinoma after histological (microscopic) examination of samples removed from the lesion sites by punch biopsy. Two applications per day of BEC to the cancer lesions resulted in ulceration of the lesion sites during treatment. However, it was observed that post treatment the wound was quickly replenished with normal tissue and that residual scarring was minimal.
CLINICAL APPRAISAL ON RESULTS FROM PHASE III Clinical Trials and OPEN STUDIES FROM ROYAL LONDON HOSPITAL
Dr Sangeeta Punjabl
MBBS DVD DipNB (Dermatology)
Research Registar, Royal London Hospital
Rino Cerio
BScFgRCP (Lond) FRCP (Edin)
Consultant Dermotologist and Senior Lecturer in Dermatopathology
Background
The Dermatology Department at the Royal London Hospital has acted as an approved and designated center in two clinical trials to determine the safety and efficacy of BEC 5 cream in the treatment of cancerous lesions of the skin. In the first of these, a pivotal double blind randomized study, Royal London recruited, treated and monitored 21 of the 94 patients. In the second trial, comprising 41 patients, Royal London was the sole designated centre. This trial was an open study, conducted primarily assess the safety of the product. Herewith we summarize our observation on the use, safety, efficacy, cosmetic result and resource effectiveness of the product.
USE
The Dermatology Department at the Royal London Hospital has acted as an approved and designated center in two clinical trials to determine the safety and efficacy of BEC 5 cream in the treatment of cancerous lesions of the skin. In the first of these, a pivotal double blind randomized study, Royal London recruited, treated and monitored 21 of the 94 patients. In the second trial, comprising 41 patients, Royal London was the sole designated centre. This trial was an open study, conducted primarily assess the safety of the product. Herewith we summarize our observation on the use, safety, efficacy, cosmetic result and resource effectiveness of the product.
In our view these results, in the least justify a more extensive clinical trial of BEC5 against such cancers. We note in this respect that treatment of the morpheoic form of the affliction is presently confined to surgical removal. We are not aware of any emerging therapy, for example, photodynamic therapy that has the potential to extend to treatment of other than superficial skin cancers.
Safety
Our clinical experience has shown that BEC5 is safe. In the two frequent (twice daily) and prolonged (8 weeks) application of a cream incorporating BEC5 under occlusive dressing resulted only in local skin irritation and erythema. Very few patients under our supervision withdrew from treatment on this account. Hence we consider treatment with BEC5 to be safe therapy.
Furthermore, patient blood and urine was analyzed using very sensitive methods to determine the presence of the BEC5 during and after a standard treatment regime (twice daily for 8 weeks). Such analysis product no evidence of the active pharmaceutical ingredients to BEC5 or their breakdown products. Hence, it was concluded that there is no systemic absorption of BEC5. This is extremely important from the clinical perspective and may be contrasted with other topical preparations. For example, 5 fluouracil shows systemic absorption and can prove to toxic when used with large lesions.
Efficacy
Royal London has a large dedicated skin cancer clinic as it is a Skin Cancer Center for the North East Thames Network. This fact, coupled with the results of the first trial, was instrumental on Royal London's conduct of second open study. Success rates in this open trial paralleled the multi-center efficacy rate of 78%. Success was defined as zero presence of basal cell carcinoma after histological examination of samples extracted from the lesion site by punch biopsy.
We consider that this rate of treatment success more than justifies the physician considering BECs as an alternative to currently predominant treatment such as surgical excision or cryotherapy.
Cosmetic Evaluation
BEC results in ulceration of the lesion site during treatment. However, we have observed that post treatment the wound is quick replenished with normal tissue and that residual scarring is minimal. Whether such scarring proves more or less extensive than that consequent upon a number of factors including lesion size, location and so on. However, it can be said that the cosmetic results offered by treatment with BEC5 are comparable to that resulting from surgical excision.
Resource Effectiveness
Basal Cell Carcinoma is a slow growing locally invasive malignant skin tumor which mainly affects Caucasians. Dermatologists, plastic surgeons and radiotherapists jointly manage the affliction, such management usually involves surgery. The risks of surgical intervention are well known.
Moreover, excision of basal cell carcinoma from the facial area often involves reconstructive, which can be both time consuming and costly. Hence an alternative, safe and efficacious method of treatment of basal cell carcinoma that does not require physician or hospital attendance must be encouraged.
In our view and experience BEC5 is a tropical preparation, which is safe and effective, ideal therapy for outpatient treatment. Hence BEC5 is a much needed alternative to surgery for basal cell carcinoma. This is the commonest cancers in Caucasians worldwide and the prevelence continues to increase with an increasing ageing population.
It is a cost effective treatment for both primary and secondary skin cancer care.
|
